events, CT had 3.47 ± 3.18 and CC had 2.57 ± 2.96 depressive events corrected for the times they had been assessed. The time during which BD patients were observed was not significantly different between the rs486055 genotypes. We found evidence that MMP-10 may be a mediator of the number of depressive phases during BD. Due to the limits of the study including the small-to-medium sample size, the naturalistic design and the possible occurrence of false-positive findings, independent analyses are warranted.
. The expression of MMPs is enhanced during many physiological conditions including wound healing, ovulation, blastocyst implantation, bone growth and angiogenesis. Inflammatory events enhance the expression of MMPs, and their activity is enhanced in many pathophysiological conditions including tumor invasion, rheumatoid arthritis, periodontal disease and atherosclerosis. The activity of MMPs increases also during blood-brain barrier dysfunction, demyelination, neuroinflammation and neurotoxicity. Consistently, MMPs are involved in a list of neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's and Parkinson's diseases [1, 3, 4] . In particular, many ECM proteins, adhesion molecules, chemokines, receptors and growth factors interact during neuronal migration, survival, synaptogenesis and plasticity. Thus, ECMs may be good candidates in the investigation of the diseases of the central nervous system, including bipolar disorder (BD). BD is a complex and frequent (1% prevalence worldwide, which rises up to 6.4% when subthreshold cases are included [5] ) neurological disease characterized by pathological mood swings, which results in tremendous social costs [6, 7] . Its biological causes are incompletely understood. As a consequence, the current pharmacological treatments do not target its molecular core and are only partially effective [7, 8] . The identification of the genetic causes of BD could pave the way to the synthesis of new and more efficacious compounds, and some lines of evidence stress the role of MMPs in BD: Rybakowski et al. [9] recently reported that MMP-9 serum levels were increased in a sample of 54 inpatients with BD (19 males, 35 females), aged 42 ± 14 years, compared to 29 subjects (15 males, 14 females), aged 40 ± 11 years, as a control group. Moreover, MMP-9 serum levels significantly correlated with the depressive phases in younger subjects (<45 years). The same group could not show a genetic impact of a variant -the -1562C/T MMP-9 gene polymorphism (rs3918242) -towards lithium prophylaxis in a sample of 109 BD patients [10] . In a previous study, the same group identified an impact of MMP-9 towards cognition in BD patients [11] . Nevertheless, conflicting results from other research groups that also focused on the possible role of MMPs in BD can be found [12] , and the small sample size and the incomplete genetic coverage decreased the power of the studies that retrieved positive association findings. Thus, further studies are needed. In the present work, we extended the analysis of the genetic impact of a list of MMPs towards depressive phases of BD patients.
Methods

Sample under Investigation
The sample under investigation was retrieved from the publicly available Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) [13] . During the study, BD patients of every subtype with ages ≥ 15 years were entered into a study registry. All patients received a systematic assessment battery at entry and were treated by a psychiatrist using a series of model practice procedures consistent with expert recommendations. At every follow-up visit, the treating psychiatrist completed a standardized assessment and assigned an operationalized clinical status based on DSM-IV criteria. Patients had independent evaluations at regular intervals throughout the study and remained under the care of the same treating psychiatrist while making transitions between randomized care studies and the standard care treatment pathways. In the present study, we only considered records from the naturalistic first phase of the study. Table 1 reports the characteristics of the sample under analysis. BD I and BD II patients were all included in the analysis to increase the power of the study. No differentiation between BD I and BD II could be made due to the lack of data (number of manic and hypomanic phases in the past). This may be considered as a limitation of the study. Nevertheless, major depressive episodes are common traits between BD I and BD II patients, which offers a rationale to include all the patients in the same genetic association study when investigating depressive phases.
Definition of the Phenotype
The ratio between the times patients were found to be definitively depressed and the times patients were observed during the phase of the study under analysis was the outcome of choice. The correlations between the phenotype of choice and a set of other phenotypes calculated at standard time points (number of depressive phases from 30, 90, 120 and so forth days from the beginning of the study) -a more classical approach to this kind of studieswere calculated. We had confirmation that the phenotype under analysis significantly correlated with almost all the phenotypes at different time points, with the advantage of having 0% of missing values. Results are reported in table 2 . The only time point at which the correlation was not significant was after 30 days from the beginning of the study. Nevertheless, the number of missing information for this time point (94%) may be held accountable for the lack of association. All patients were treated in a naturalistic environment according to the international guidelines for the treatment of BD. Thus, the authors interpreted the phenotype under analysis as a measure of the efficacy of the pharmacological treatments administered to patients. This phenotype could also be related to depressive phases per se, rather than to the impact of the pharmacological treatments. The genetic effect could then be related to the course of disease rather than to the impact of the pharmacological treatments.
Study of Stratification Factors
The sociodemographic and clinical variables were investigated as possible stratification factors. A story of treatment for alcoholrelated problems was found to be significantly associated with the outcome as was included in the analysis. Treatment (combination of treatments) correlated with the number of depressive episodes during the period of observation and was included in the analysis. Table 3 reports the details of the treatments delivered to subjects under analysis during phase 1 of the study. The higher the number of depressive events during the period of observation, the higher the rate of administration of a combination of treatments with antipsychotics, mood stabilizers and antidepressants. The administration of an antidepressant alone did not correlate with the number of depressive events, consistent with the literature and guidelines in the field.
Power of the Study
We had sufficient power (0.80) to detect a small-to-medium effect size (0.22) between two allelic frequencies, each represented by at least 300 subjects (R-cran pwr package used for the analysis).
Selection of Genes
Genes that belong to the MMP family that were used for the analysis are reported in table 4 . Imputation was run for the genes that belong to the pathway under analysis in order to decrease the computational effort. The CEU HapMap 1,000 genomes served for the analysis. From the original (not pruned) set of 203 single-nucleotide polymorphisms from the pathway under analysis we obtained 43 that passed the imputation quality control (info >0.9) and the pruning (r 2 > 0.2). Pruning was undertaken after imputation.
Statistical Methods
Covariate linear regression was the statistical model for the analysis. PLINK was used for the analysis [14] . The p value for a significant result was set at 0.05/43 = 0.001 (Bonferroni correction).
Results
rs486055 in the MMP10 gene was found associated with the number of depressive events corrected for the number of total visits during the period of observation (p = 0.0004; t = 3.68). In particular, TT homozygotes (n = 10) had 5.08 ± 3.51 events, CT (n = 131) had 3.47 ± 3.18 and CC (n = 359) had 2.57 ± 2.96 depressive events corrected for times they had been assessed during the period of observation (Hardy-Weinberg equilibrium, p = 0.58). The time during which BD patients were observed during the period included in the analysis was not significantly different between the rs486055 genotypes (TT = 15 ± 10.28; CT = 20.49 ± 13.47; CC = 17.98 ± 13.57; t = 1.18; p = 0.23).
Discussion
We found evidence that the rs486055 C/T nonsynonymous (R53K) exonic variant in MMP-10 impacts on the number of depressive events during BD. The implication of this extracellular enzyme in response to treatment during bipolar depression is new in the literature. In the brain, MMPs comprise a family of over 20 endo- Missing: percentage of subjects that lack the investigated value at a certain time point; conf1 = upper confidence limit; conf2 = lower confidence limit. 80 peptidases synthesized and secreted by both neuronal and glial cells. These enzymes serve as effectors of many brain cellular functions, such as migration, cytotoxicity, tissue remodeling, cell behavior and cell-cell communication via degradation of ECM components. In particular, they play a critical role in the degradation and/or proteolytic processing of many ECM factors, including growth factors, cytokines, chemokines, adhesion molecules and other proteins of the cell surface, proteases, intercellular junction proteins and structural molecules. Moreover, MMPs have been implicated in numerous neurological diseases, including multiple sclerosis, amyotrophic lateral sclerosis and other neuromuscular diseases, neurodegenerative diseases, such as Alzheimer's disease and Huntington's disease, as well as epilepsy, addiction, fragile-X syndrome and autism [15] [16] [17] [18] [19] [20] [21] [22] [23] . The association of a polymorphism in an MMP gene and the BD is not surprising, as it has been previously demonstrated that the functional -1562C/T polymorphism of the MMP9 gene segregates in BD [24] . Moreover, a polymorphism in MMP9 was associated with schizophrenia, suggesting that the MMP9 gene may be a common susceptibility gene to major psychoses [25] , further supporting the overlap between the genetic loci and alleles that predispose to these disorders [26, 27] . While the role of many MMPs, including MMP-2, MMP-3, MMP-7 and especially MMP-9, in synaptic plasticity, remodeling and spine morphology is well established [28] [29] [30] [31] [32] [33] [34] [35] [36] , and their alteration is known to be associated with neuropathological and psychiatric conditions [22, 32, 33, 37, 38] , MMP-10 has never been correlated before either with brain plasticity or with neuropathologies. On the other hand, MMP-10 is known to be upregulated in brain tumors [39, 40] , ischemic neurons after stroke [41, 42] and cerebrospinal fluid of cerebral adrenoleukodystrophy [43] , sustaining the role of this MMP in neurodegeneration. In agreement with that, a role of MMP-10 has been demonstrated in Huntington's disease, as MMP-10 is involved in the pathological cleavage of hungtingtin, leading to the production of toxic huntingtin fragments in striatal neurons [19] . However, considering that there are now many lines of evidence showing that synaptic plasticity is dysfunctional in BD [44, 45] and that MMPs, including MMP-10, are involved in the tiny regulated proteolysis of many ECM substrates involved in synaptic plasticity, it is tempting to speculate that the correlation between the MMP-10 exonic variants and the number of depressive events could be related to the possible role of MMP-10 in brain plasticity, through proteolysis of the ECM proteins involved in neurotransmission between neurons or between neurons and glial cells. In particular, the contribution of MMP-10 to brain inflammation, which is mainly related to the activity of the glial cells [46] [47] [48] , and the relevance of neuroinflammation in BD [49] [50] [51] , leads to a possible hypothesis of an MMP-10-related imbalance in neuron-glia interactions in synaptic plasticity alteration in BD somehow linked to neuroinflammation. The present study is limited by the small-to-medium sample size that may have decreased the power of the study to the point that small but true genetic effects went undetected. To limit this caveat we designed a specific output for the analysis in order to enroll as many patients as possible. The demonstration that this outcome was significantly correlated with a number of other possible outcomes calculated with more classical methods, confirmed the validity of our analysis. Nevertheless, more independent studies are needed to confirm the role of rs486055 in shaping the risk of a nonresponse to common pharmacological treatments during the depressive phases of BD. Another possible limit of the study depends on the naturalistic design of the STEP-BD study. We could only control statistically for this caveat. Moreover, a higher external validity versus a lower internal validity is a classical advantage of a naturalistic design. For a more thorough analysis of this relevant methodological issue, please refer to Tunis et al. [52] . Our findings should be considered as suggestive, waiting for a confirmation by a more strict and classic pharmacogenetic approach. Finally, this kind of investigations is biased towards false-positive findings [53] . We tried to face this limit by applying a strict threshold. Nevertheless, this approach, despite being statistically sound, may be ineffective concerning the true biological correlations.
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